Financial Data and Key Metrics Changes - The group's total revenue increased by 4.2% to CNY 14.151 billion, with net profit rising by 10.8% to CNY 1.372 billion [5][6][8] - Gross profit rose by 3.4% to CNY 6.063 billion, while the gross profit margin was 42.8% [6][8] - Net cash increased by 73.4% to CNY 1.707 billion, and net asset value per share rose by 12.3% to CNY 3.64 [6][9] Business Line Data and Key Metrics Changes - Revenue from the Xtep core brand grew by 1.5% to CNY 12.515 billion, while the professional sports segment, including Saucony and Merrell, saw revenue growth of over 30% to CNY 1.636 billion [5][11] - Operating profit for the professional sports sector rose by 46.4% year-on-year to CNY 114 million, with an operating profit margin of 7% [11][12] Market Data and Key Metrics Changes - The number of runners in China increased from fewer than 90 million to 300 million by 2025, with marathon participants growing by over 20% annually [2] - Xtep maintained the number one position in overall wear rates at major marathon events in China [2][16] Company Strategy and Development Direction - The company aims to solidify its position as China's number one running brand, focusing on running as a core strategy and enhancing brand quality and efficiency [4][25] - Plans include expanding product offerings, optimizing retail channels, and enhancing e-commerce capabilities [18][25] Management's Comments on Operating Environment and Future Outlook - The management acknowledged a complex and volatile global economic environment but emphasized steady growth driven by a focus on running [2][4] - The company anticipates significant growth opportunities in the national sports industry, projected to exceed CNY 7 trillion by 2030 [4] Other Important Information - The company has maintained a dividend payout ratio of no less than 50% for 18 consecutive years, with an annual dividend payout ratio of 50.4% [6][7] - The company is committed to sustainable development and social responsibility, including recycling initiatives and donations exceeding CNY 64 million [24][25] Q&A Session Summary Question: What are the growth strategies for the Xtep core brand? - The company will continue to focus on running, using flagship products as growth engines and expanding the product matrix [25] Question: How is the company addressing e-commerce growth? - E-commerce for the Xtep core brand achieved double-digit growth, accounting for over 30% of revenue, with plans to enhance flagship products [18] Question: What are the future plans for Saucony and Merrell? - Saucony will maintain its premium positioning and focus on professional products, while Merrell will concentrate on outdoor sports [21][24]

Financial Data and Key Metrics Changes - The company's total revenue for 2025 was RMB 82.24 billion, a year-on-year decrease of 7.3, which was in line with expectations. Sales volume fell by around 4%, while the average selling price declined by around 3% [3][4] - The gross profit margin reached a record high of 39.9%, an increase of 0.3 percentage points from 39.6% in 2024. Operating profit was RMB 6.56 billion, with an operating profit margin of 8.0%, a slight decrease of 0.2 percentage points year-on-year [4] - Adjusted profit attributable to owners was RMB 3.96 billion, excluding non-recurring impairments [4] Business Line Data and Key Metrics Changes - The liquid milk business faced pressure overall in 2025, but the second half showed signs of stabilization and improvement. Segments such as fresh milk, infant milk formula, and adult milk formula achieved double-digit growth, with cheese growth exceeding 20% [5][6] - Selling expenses fell by 6.5% to RMB 21.59 billion, but the selling expense ratio and administrative expenses ratio rose slightly due to negative operating leverage [6] - The fresh milk business achieved double-digit growth, with market share increasing further, while the ice cream business also saw double-digit growth with improved profitability [15][16] Market Data and Key Metrics Changes - Mengniu maintained its position as the top market leader in the chilled sector for 21 consecutive years, with significant growth in the cheese segment, particularly in Southeast Asia [12][17] - The company reported strong growth in the Southeast Asian market, especially in Vietnam, with sales doubling within the year [19] Company Strategy and Development Direction - Mengniu is focusing on creating long-term value for consumers rather than engaging in low-price competition. The company aims to enhance its cash generation capabilities and increase shareholder returns through a three-year shareholder return plan [8][9] - The company is committed to digital intelligence transformation, R&D innovation, channel upgrading, and brand-led strategies to lead the industry into a new cycle of high-quality development [24][25] - Mengniu is expanding its product portfolio to include high-quality protein products and specialized medical foods, addressing diverse consumer needs [30][28] Management's Comments on Operating Environment and Future Outlook - The management noted that the dairy industry is benefiting from policy and market factors, with a clear trend towards recovery. China's per capita milk consumption is significantly lower than the global average, indicating substantial growth potential [22][23] - The company believes that the dairy industry remains a sector full of imagination and worth investing in, with opportunities for growth in functional and solid dairy products [24][27] Other Important Information - Mengniu has made solid progress on key ESG issues, being recognized in sustainability indices and maintaining an AA level MSCI ESG rating [21] - The company is enhancing its presence in lower-tier markets and expanding its omni-channel operational capabilities [12][31] Q&A Session Summary Question: What are the growth prospects for Mengniu in the coming years? - The management highlighted that the dairy industry is stabilizing and recovering, with significant growth potential in functional nutrition as China's per capita GDP has crossed the $13,000 threshold, indicating a period of explosive growth for the functional nutrition market [27][24] Question: How is Mengniu addressing the challenges in the liquid milk business? - The company is focusing on innovation and product diversification to navigate challenges, with signs of stabilization in the second half of 2025 [5][6]

Financial Data and Key Metrics Changes - The company's total revenue for 2025 was CNY 82.24 billion, a year-on-year decrease of 7.3%, which was in line with expectations. Sales volume fell by around 4%, while the average selling price declined by around 3% [2][3] - The gross profit margin reached a record high of 39.9%, an increase of 0.3 percentage points from 39.6% in 2024. Operating profit was CNY 6.56 billion, with an operating profit margin of 8.0%, a slight decrease of 0.2 percentage points year-on-year [3] - Adjusted profit attributable to owners was CNY 3.96 billion, excluding non-recurring impairments [3] Business Line Data and Key Metrics Changes - The liquid milk business faced pressure overall in 2025, but the second half showed signs of stabilization and improvement. Segments such as fresh milk, infant milk formula, and adult milk formula achieved double-digit growth, with cheese growth exceeding 20% [4][5] - Selling expenses fell by 6.5% to CNY 21.59 billion, but the selling expense ratio and administrative expenses ratio rose slightly due to negative operating leverage [5] - The fresh milk business achieved double-digit growth, with market share increasing further, while the ice cream business also saw double-digit growth in 2025 [12][13] Market Data and Key Metrics Changes - The Southeast Asia market, particularly Vietnam, performed well, with cheese segment growth exceeding 20% [15][17] - Mengniu's cheese segment demonstrated robust growth, consolidating its leadership position in both B2C and B2B sectors [15] - The company is expanding its presence in lower-tier markets and increasing penetration of product categories [11][17] Company Strategy and Development Direction - Mengniu is focusing on innovation and high-quality development, steering clear of low-price competition. The company aims to create long-term value for consumers [4][5] - A three-year shareholder return plan has been formulated, with a steady increase in dividends per share and maintenance of share buyback pace [8] - The company is committed to enhancing its cash generation capabilities and has tightened control over capital expenditures [6][7] Management's Comments on Operating Environment and Future Outlook - The dairy industry is benefiting from policy and market factors, with a clear trend towards recovery. The company believes that China's dairy industry remains a sector full of potential [20][21] - Management highlighted the importance of digital intelligence transformation and R&D innovation to drive high-quality development [21][22] - The company aims to meet the diverse and personalized needs of consumers, focusing on high-quality nutrition and expanding market coverage [22][23] Other Important Information - Mengniu has made significant progress in ESG initiatives, being recognized in sustainability indices and maintaining a strong ESG rating [19] - The company is enhancing its product portfolio with a focus on functional nutrition and medical nutrition, tapping into niche demands [25][26] Q&A Session Summary Question: What are the growth prospects for Mengniu in the coming years? - Management expressed confidence in the recovery of the dairy industry, supported by favorable policies and market conditions, and emphasized the company's commitment to innovation and value creation [20][21] Question: How is Mengniu addressing the challenges in the liquid milk business? - The company is focusing on product innovation and optimizing its product mix to navigate economic cycles and enhance resilience [4][5] Question: What are the plans for expanding in international markets? - Mengniu is strengthening its presence in Southeast Asia and expanding into new markets like Indonesia and the Philippines, leveraging existing brands and product categories [17][18]

Financial Data and Key Metrics Changes - The company's total revenue for 2025 was RMB 82.24 billion, a year-on-year decrease of 7.3%, which was in line with expectations. Sales volume fell by around 4%, while the average selling price declined by around 3% [3][4] - The gross profit margin reached a record high of 39.9%, an increase of 0.3 percentage points from 39.6% in 2024. Operating profit was RMB 6.56 billion, with an operating profit margin of 8.0%, a slight decrease of 0.2 percentage points year-on-year [4] - Adjusted profit attributable to owners was RMB 3.96 billion, excluding non-recurring impairments [4] Business Line Data and Key Metrics Changes - The liquid milk business faced pressure, but the second half of 2025 showed signs of stabilization. Segments such as fresh milk, infant milk formula, and adult milk formula achieved double-digit growth, with cheese growth exceeding 20% [5][6] - Selling expenses fell by 6.5% to RMB 21.59 billion, but the selling expense ratio and administrative expenses ratio rose slightly due to negative operating leverage [6] - The fresh milk business achieved double-digit growth, with market share increasing further, while the ice cream business also saw double-digit growth in 2025 [15][16] Market Data and Key Metrics Changes - Mengniu maintained its position as the top market leader in the chilled sector for 21 consecutive years, with significant growth in the cheese segment, particularly in Southeast Asia [12][17] - The company experienced strong growth momentum in the Southeast Asian market, especially in Vietnam, with sales doubling within the year [19][20] Company Strategy and Development Direction - Mengniu is focusing on innovation and high-quality development, steering clear of low-price competition. The company aims to create long-term value for consumers and enhance its cash generation capabilities [5][8] - The company has formulated a three-year shareholder return plan, increasing dividends per share and maintaining share buyback pace [9] - Mengniu's strategy includes enhancing digital intelligence transformation, R&D innovation, channel upgrading, and brand-led initiatives to lead the industry into a new cycle of high-quality development [24][25] Management's Comments on Operating Environment and Future Outlook - The dairy industry is expected to benefit from policy and market factors, with a clear trend towards recovery. China's per capita milk consumption is significantly lower than the global average, indicating substantial growth potential [22][23] - The company believes that the dairy industry remains a sector full of imagination and worth investing in, with opportunities presented by favorable policy environments and industry recovery [24][27] Other Important Information - Mengniu has made solid progress on key ESG issues, being recognized in various sustainability indices and maintaining an AA rating from MSCI [21] - The company is committed to advancing its sustainability strategy and creating social value through industrial value [21] Q&A Session Summary Question: What are the growth prospects for Mengniu in the coming years? - Mengniu anticipates that the dairy industry will stabilize and recover, with significant growth potential due to low per capita milk consumption in China compared to global averages [22][23] Question: How is Mengniu addressing the challenges in the liquid milk business? - The company is focusing on innovation and product diversification to navigate economic cycles and enhance resilience, with signs of stabilization in the second half of 2025 [5][6]

Financial Data and Key Metrics Changes - The total revenue for the company in 2025 was CNY 82.24 billion, representing a year-on-year decrease of 7.3%, which was in line with expectations [2] - The overall sales volume fell by around 4%, while the average selling price declined by around 3% [2] - The gross profit margin reached a record high of 39.9%, an increase of 0.3 percentage points from 39.6% in 2024 [3] - The operating profit for the full year was CNY 6.56 billion, with an operating profit margin of 8.0%, a slight decrease of 0.2 percentage points over the previous year [3] - Adjusted profit attributable to owners was RMB 3.96 billion, excluding non-recurring impairments [3] Business Line Data and Key Metrics Changes - The liquid milk business faced overall pressure in 2025, but the second half showed signs of stabilization and improvement compared to the first half [4] - Segments such as fresh milk, infant milk formula, and adult milk formula achieved double-digit growth, with cheese growth exceeding 20% [5] - Selling expenses fell by 6.5% to CNY 21.59 billion, although the selling expense ratio and administrative expenses ratio rose slightly due to negative operating leverage [5] - The fresh milk business achieved double-digit growth, with market share increasing further [12] - The ice cream business also saw double-digit growth in 2025, with profitability increasing [12] Market Data and Key Metrics Changes - The Southeast Asia market, particularly Vietnam, performed particularly well, with cheese demonstrating robust growth exceeding 20% [15] - The company is expanding its presence in lower-tier markets and increasing penetration of product categories [10] - The dairy industry in China is expected to benefit from policy and market factors, with a significant gap in per capita milk consumption compared to global averages [20][21] Company Strategy and Development Direction - The company aims to create long-term value for consumers by shifting focus from competition to value creation [5] - Mengniu is committed to enhancing cash generation capabilities and has formulated a three-year shareholder return plan [7] - The company is focusing on digital intelligence transformation, R&D innovation, channel upgrading, and brand-led strategies to drive high-quality development [22] - Mengniu is transitioning from a traditional dairy manufacturer to a comprehensive nutrition and health solutions provider [32] Management's Comments on Operating Environment and Future Outlook - The management highlighted that the dairy industry has bottomed out and stabilized, with a clear trend towards recovery [22] - There is a belief that China's dairy industry remains a sector full of imagination and worth investing in [21] - The company plans to enhance its value creation capabilities through the evolution of core competencies [22] - The management emphasized the importance of product innovation and expanding demand in the functional nutrition market [25] Other Important Information - Mengniu has made solid progress on key ESG issues and has been recognized for its sustainability efforts [19] - The company launched several new products, including lactose-free milk and premium beverages, to meet diverse consumer needs [9][10] - Mengniu's marketing strategies have successfully integrated brand exposure with sales conversion, particularly during significant events like the Winter Olympics [31] Q&A Session Summary Question: What are the growth prospects for Mengniu in the coming years? - The company believes that the dairy industry in China is poised for growth, with significant potential for increased consumption as per capita milk consumption is still low compared to global averages [20][21] Question: How is Mengniu addressing the challenges in the liquid milk business? - The management noted that innovative measures have been implemented to stabilize the business, with signs of improvement in the second half of 2025 [4] Question: What is the company's approach to shareholder returns? - Mengniu has set a steady increase in dividends per share and plans to maintain share buyback pace to enhance shareholder returns [7]

Financial Data and Key Metrics Changes - In 2025, total revenue reached RMB 2.37 billion, representing a 135% year-over-year growth [4][15] - Product sales amounted to RMB 1.44 billion, up 43% from the previous year [4][15] - The company achieved a net profit of RMB 644 million, marking its first profitable year [4][15] - Cash position at the end of 2025 was RMB 2.8 billion, supporting ongoing R&D investments [5][16] - R&D expenses were RMB 950 million, reflecting a 16.9% year-over-year growth [16] Business Line Data and Key Metrics Changes - Orelabrutinib received regulatory approval for multiple indications, significantly expanding its commercial space [10][11] - Tafasitamab was approved for DLBCL in mainland China, enhancing the company's oncology portfolio [10][20] - Mesutoclax is being developed for four indications, with ongoing clinical trials showing promising results [11][25] Market Data and Key Metrics Changes - The global partnership strategy yielded a total business development deal value exceeding $2.5 billion in 2025 [5][18] - The company is focusing on expanding its presence in both domestic and international markets, with significant breakthroughs in globalization [18][19] Company Strategy and Development Direction - The company aims to become a global pharmaceutical leader by focusing on oncology and autoimmune diseases [4] - A diversified product portfolio is being developed, transitioning into multiple commercial and late-stage assets [15][17] - The company is investing in innovative platforms such as ADC and molecular glue technologies to enhance its R&D capabilities [16][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over 35% growth in drug sales for 2026, driven by Orelabrutinib and new product launches [17][54] - The company anticipates continued profitability and sustainable growth, supported by a strong pipeline and business development opportunities [55][62] Other Important Information - The company has over 10 phase III registrational studies ongoing, with multiple major products expected to receive regulatory approvals in the next two to three years [14][19] - The first ADC product, ICP-B794, is in the dose escalation stage of phase I trials, showing promising preliminary results [40][46] Q&A Session Summary Question: What is the sales potential for Orelabrutinib in 2026? - Management expects Orelabrutinib to continue growing over 30% due to deeper penetration in CLL and MCL, along with broader hospital coverage [51][53] Question: What is the development plan for ICP-488 overseas? - The company plans to expand indications after the phase III readout and is open to partnerships for global development [57][59] Question: What is the forecast for R&D expenses in 2026? - R&D expenses are expected to grow by around 20% in 2026, focusing on late-stage clinical studies and innovation platforms [61][62] Question: How will ICP-488 position itself against competitors in the psoriasis market? - The company believes its TYK2 inhibitor has a broader potential compared to oral IL-23 therapies, targeting multiple autoimmune diseases [73][75] Question: What are the inclusion criteria for the Orelabrutinib plus Mesutoclax data? - The combination therapy shows promising results in unfit older patients, providing a good treatment option for this population [78]

Financial Data and Key Metrics Changes - In 2025, total revenue reached RMB 2.37 billion, representing a 135% year-over-year growth [4][15] - Product sales reached RMB 1.44 billion, up 43% over the previous year [4][15] - Net profit reached RMB 644 million, marking the company's first year with a profit [4][17] - Cash position at the end of 2025 was RMB 2.8 billion, supporting continued R&D investment [5][17] - R&D expenses were RMB 950 million, reflecting a 16.9% year-over-year growth [17][61] Business Line Data and Key Metrics Changes - Orelabrutinib was approved for first-line treatment of CLL/SLL and included in NRDL, expanding commercial space [5][11] - Tafasitamab was approved for DLBCL in mainland China, enhancing the company's oncology portfolio [5][11] - Zurletrectinib was approved for marketing in China, marking the company's first approved therapy in solid tumors [11][40] Market Data and Key Metrics Changes - The company entered into strategic collaborations with Zenas BioPharma and Freelium, unlocking significant value with total BD deal value exceeding $2.5 billion [5][19] - Globalization is becoming a key growth pillar, with major out-license transactions covering four assets [19] Company Strategy and Development Direction - The company aims to become a global pharmaceutical leader focused on innovative therapies for oncology and autoimmune diseases [4] - A diversified product portfolio is being developed, with multiple commercial and late-stage assets driving future expansion [15][18] - The company is investing in next-generation platforms such as ADC and molecular glue technologies [17][61] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over 35% growth in drug sales for 2026, driven by Orelabrutinib, Tafasitamab, and Zurletrectinib [18][54] - The company achieved profitability ahead of schedule, with expectations for sustainable breakeven in 2026 and 2027 [54][56] Other Important Information - The company has over 10 phase III registrational studies ongoing globally, with multiple major products expected to receive regulatory approvals in the next 2-3 years [14][20] - The pipeline includes innovative therapies for autoimmune diseases, with significant market potential exceeding $150 billion [36][29] Q&A Session Summary Question: What is the sales potential for Orelabrutinib in 2026? - Management expects continued growth over 30% for Orelabrutinib, driven by deeper penetration in CLL and MCL, and broader hospital coverage [52][53] Question: What is the development plan for ICP-488 overseas? - The company plans to expand indications after the phase III readout and is open to partnerships for global development [57][59] Question: What is the forecast for R&D expenses in 2026? - R&D expenses are expected to grow around 20% in 2026, focusing on late-stage clinical studies and innovation platforms [61][62] Question: How will the company position its TYK2 inhibitors amid competition? - The company believes its TYK2 inhibitors have broader potential beyond psoriasis, targeting multiple autoimmune diseases [72][73] Question: What are the inclusion criteria for the Orelabrutinib plus Mesutoclax data? - The combination therapy targets unfit older patients, achieving a 65% MRD-negative rate, demonstrating good results in this population [79]

Financial Data and Key Metrics Changes - Revenue reached RMB 21.8 billion, a 16.7% increase from 2024, with a sequential growth of about 18% in the second half compared to the first half [25][26] - Adjusted net profit increased by 22% year-over-year to RMB 6.6 billion, with a margin expansion of 130 basis points to 30.2% [32][34] - Adjusted EBITDA rose by 22.8% to RMB 9.8 billion, with an adjusted EBITDA margin of 45.1%, one of the highest in the global CDMO industry [32][34] Business Line Data and Key Metrics Changes - Research and discovery services saw a doubling of upfront payments to $115 million, with potential milestone income streams exceeding $4 billion [27] - Development revenue grew by approximately 32% year-over-year, driven by 209 new projects, with 186 in the pre-IND space [28] - Manufacturing revenue from late-phase and commercial projects grew over 26% year-over-year, now representing over 43% of the total portfolio [29] Market Data and Key Metrics Changes - The U.S. accounted for 58% of revenue, growing over 18%, while Europe contributed 23% with nearly 17% growth [16] - Japan and Korea experienced significant growth of almost 70%, now representing 6.5% of total revenue [16][17] - China saw a slight decline in revenue, but adjusting for out-licensing deals shows nearly flat year-over-year growth [17][18] Company Strategy and Development Direction - The company emphasizes a unique CRDMO business model, focusing on bi-specifics, ADCs, and traditional mAbs to drive sustainable high growth [3][4] - The strategy includes expanding capabilities in complex modalities, which are expected to enhance market share due to their challenging nature [20][21] - Continuous investment in technology and capacity expansion in key markets like the U.S. and Singapore is planned to support future growth [59][60] Management's Comments on Operating Environment and Future Outlook - Management acknowledges geopolitical uncertainties but remains optimistic about sustained growth driven by a strong project funnel and client trust [8][14] - The company expects to continue delivering high growth, with a focus on maintaining a sticky project funnel despite external challenges [14][19] - Future revenue growth is anticipated from the successful execution of projects and the introduction of new technologies [58][64] Other Important Information - The company reported a significant increase in gross profit, reaching over RMB 10 billion, with a 31% increase in gross profit margin [30][37] - The company has a strong balance sheet with RMB 15.7 billion in cash, supporting accelerated global growth [41][43] - The company is committed to continuous improvement through the WuXi Business System, achieving a 150 basis points improvement in margin [70] Q&A Session Summary Question: What are the key drivers of revenue growth? - Revenue growth was driven by R&D services, particularly in bispecifics and ADCs, with a strong pipeline of new deals expected to continue into 2026 [27][28] Question: How does the company plan to manage geopolitical risks? - The company acknowledges the geopolitical noise but emphasizes the stickiness of its project funnel and strong client relationships as mitigative factors [8][14] Question: What is the outlook for the manufacturing segment? - The manufacturing segment is expected to grow significantly, with a focus on late-phase projects and commercial manufacturing, which have shown strong revenue growth [29][30]

Financial Data and Key Metrics Changes - Revenue reached RMB 21.8 billion, a 16.7% increase from 2024, with a sequential growth of about 18% in the second half compared to the first half [25][26] - Adjusted net profit increased by 22% year-over-year to RMB 6.6 billion, with a margin expansion of 130 basis points to 30.2% [32][33] - Basic earnings per share grew from $0.82 to $1.22, a 49% increase [36] Business Line Data and Key Metrics Changes - Research and discovery services saw a doubling of upfront payments to $115 million, with potential milestone income streams exceeding $4 billion [26][27] - Development revenue grew by about 32% year-over-year, driven by 209 new projects, with 186 in the pre-IND space [28] - Manufacturing revenue from late-phase and commercial projects grew over 26% year-over-year, now representing over 43% of the total portfolio [29] Market Data and Key Metrics Changes - U.S. revenue accounted for 58% of total revenue, growing over 18%, while Europe contributed 23% with nearly 17% growth [16] - Japan and Korea experienced almost 70% growth, now making up 6.5% of total revenue [16] - China saw a slight decline in revenue, but adjusting for out-licensing deals shows a flat year-over-year growth [17] Company Strategy and Development Direction - The company emphasizes a unique CRDMO business model, focusing on bi-specifics, ADCs, and traditional mAbs to drive sustainable growth [3][4] - The strategy includes expanding capabilities in complex modalities, which are expected to enhance market share due to their challenging nature [20] - Continuous investment in technology and capacity expansion is planned, particularly in the U.S. and Singapore, to support future growth [59][60] Management's Comments on Operating Environment and Future Outlook - Management acknowledges geopolitical uncertainties but remains optimistic about revenue growth driven by a strong project funnel and backlog [25][30] - The company expects to maintain momentum in R&D and development services, with a focus on innovative platforms and complex modalities [26][28] - Future revenue growth is anticipated from the successful execution of projects and the expansion of manufacturing capabilities [29][58] Other Important Information - The company reported a significant increase in gross profit, reaching over RMB 10 billion, a 31% increase year-over-year [30] - The adjusted gross profit margin reached 48.8%, with a 340 basis points improvement year-over-year [37] - The company has a strong balance sheet with RMB 15.7 billion in cash, supporting accelerated global growth [41] Q&A Session Summary Question: What is the outlook for revenue growth in the coming years? - Management indicated that the revenue growth is expected to continue, driven by a strong project pipeline and successful execution of existing projects [25][30] Question: How does the company plan to address geopolitical uncertainties? - The company is focusing on diversifying its revenue streams and maintaining strong relationships with clients to mitigate risks associated with geopolitical issues [25][30] Question: What are the key drivers for the growth in the U.S. and European markets? - The growth in these markets is attributed to the increasing demand for complex modalities and the successful execution of large-scale projects [16][29]

Financial Data and Key Metrics Changes - In 2025, the group's total revenue reached RMB 9.68 billion, representing a year-on-year decrease of 6% [6][23] - Revenue from office software and services was RMB 5.93 billion, up 16% year-on-year, while revenue from online games and other businesses was RMB 3.75 billion, up 28% year-on-year [6][23] - Gross profit margin decreased by 2 percentage points year-on-year to 81% [23] - Profit attributable to owners of the parent was RMB 2.00 billion for 2025, compared to RMB 1.75 billion for the previous year [23] Business Line Data and Key Metrics Changes - Kingsoft Office Group's total annual revenue reached RMB 5.93 billion, up 60% year-on-year, with fourth-quarter revenue of RMB 1.75 billion, up 17% year-on-year [7][8] - WPS individual business revenue reached RMB 3.63 billion, up 10% year-on-year, with fourth-quarter revenue of RMB 960 million, growing 14% year-on-year [9] - WPS 365 business revenue was RMB 720 million, up 65% year-on-year, with fourth-quarter revenue of RMB 210 million, up 16% year-on-year [10] - WPS software business revenue reached RMB 1.46 billion, up 15% year-on-year, with fourth-quarter revenue of RMB 530 million, up 16% year-on-year [12] Market Data and Key Metrics Changes - The cumulative number of annual paid individual users in domestic markets reached 6.2 million, up 11% year-on-year [9] - Monthly active users for WPS AI surpassed 18 million, presenting a year-over-year increase of 307% [9] - In overseas markets, the cumulative number of paying users grew significantly, with monthly active devices for the overseas PC version reaching 42.5 million, up 54% year-on-year [9] Company Strategy and Development Direction - The company is committed to technology empowerment, focusing on AI collaboration and internationalization [4] - Kingsoft Office Group is pursuing a dual-track approach, enhancing existing products while exploring new AI office paradigms [7] - The online game business aims to deepen expertise in classical IP and expand into diversified game categories and global markets [4][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential for growth in the online gaming sector, particularly with the successful launch of new titles [15] - The company plans to deepen the application of AI agent technology in office environments and accelerate its international strategy [15] - Management acknowledged the challenges faced in the gaming sector but emphasized the importance of maintaining high-quality service and user engagement [32][36] Other Important Information - The company had cash resources of RMB 27 billion as of December 31, 2025 [24] - Net cash generated from operating activities was RMB 2.29 billion for the year ended December 31, 2025 [24] Q&A Session Summary Question: What strategic adjustments have been made regarding the future development of the gaming business? - Management indicated that the focus is on stabilizing user engagement and planning for future game versions to enhance daily active users [27][29] Question: Insights on the user base and retention metrics for Goose Goose Duck? - The game has over 30 million new users since launch, with a stable user base around 3 million [27][28] Question: What is the progress of the AI business and the development of industry-specific models? - The company has established an AI Product Center and is focusing on empowering different industries through AI [41][43] Question: How will Xiaomi's MiMo-V2 model enhance the WPS business? - Management emphasized the need to strengthen competitive capabilities and enhance the AI ecosystem in collaboration with Xiaomi [49][50]